Britain has secured a landmark deal with the US that will increase UK medicines spending in exchange for exemption from threatened 100 per cent tariffs on pharmaceutical imports. The agreement promises billions of pounds in extra funding for innovative medicines over the next decade, raising the threshold at which the National Institute for Health and Care Excellence judges treatments cost-effective from £20,000-£30,000 to £25,000-£35,000 per year of good-quality life.

Eli Lilly and other pharmaceutical giants had paused UK investments, citing concerns about insufficient drug pricing. Lord Patrick Vallance, UK science minister, said the deal would restore Britain to the forefront of life sciences globally. The agreement includes a commitment to increase medicines spending from 0.3 per cent of GDP to 0.35 per cent by 2028 and 0.6 per cent by 2035, while also establishing closer regulatory alignment between US and UK medical technology approvals.

The pharmaceutical industry has welcomed the deal as a signal that the government is listening to business concerns. However, Vallance warned against further demands for threshold increases, stating that the recent adjustment was sufficient. The agreement represents a significant shift in UK healthcare policy, prioritizing pharmaceutical investment over previous cost-containment measures that had drawn criticism from major drugmakers.